It demonstrated that administration of MRS2578 has potential to directly modulate the expression and activities of MMP-2 and MMP-9 in a dose-dependent manner followed by elastic fiber degradation and disruption of media, which may explain the higher AAA rupture-related mortality in the MRS2578-cotreated group. The gene discussed is MMP9; the disease is triple-A syndrome.